| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oxford Immunotec reported today a 27 percent year-over-year increase in first quarter revenues primarily on growth in tuberculosis testing in all geographies.
For the three months ended March 31, 2019, Oxford Immunotec logged $14.8 million in total revenues compared to $11.7 million in the year-ago period. On a constant-currency basis, Q1 revenues increased 39 percent year over year.
On a conference call following release of the company's earnings, Oxford Immunotec CEO Peter Wrighton-Smith noted that revenues came in above the company's implied guidance range of $13.4 million to $14.1 million.
Investors with a long-term horizong may find it valuable to assess Quest Diagnostics Incorporated's (NYSE:DGX) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. Below is my commentary, albiet very simple and high-level, on how Quest Diagnostics is currently performing.
Before diving into an analysis of these and similar questions, it’s important to get on the same page regarding the substance. Cannabidiol – or CBD – is a chemical found in marijuana and its close relative, hemp. Pure CBD does not contain tetrahydrocannabinol (THC), the psychoactive ingredient found in marijuana that produces a high.[CR-LF][CR-LF]The most common CBD formulation started as oil, but CBD is also sold as an extract, a vaporized liquid, and an oil-based capsule. CBD-infused beverages are probably the most common CBD product, but use of CBD-based cosmetic and skincare products is surging in both retail stores and online.[CR-LF][CR-LF]This means that one of your workers or applicants might think they are staying on the right side of the law when using a CBD product, but could inadvertently ingest substances that violate your valid drug policies. Barry Sample, the Director of Science and Technology for the drug testing laboratory Quest Diagnostics, recently observed that the government is not ensuring the level of THC remains low because CBD oil is not regulated in the United States. Therefore, he said, “if somebody is using a CBD oil that contains residual THC in it, they very likely could test positive on a urine drug test. Not because of the CBD itself – but because of a contaminant that is in that oil.”
Shares of LabCorp moved lower following the afternoon disclosure and are trading down $1.51 to $164.12. LabCorp competitor Quest Diagnostics (DGX) gave up some of its gains as well but the shares remain up 51c to $98.67 in afternoon trading.
While the ultimate impact of UnitedHealthcare's newly launched Preferred Laboratory Network remains to be seen, some clinical lab players are suggesting it could be the first step in a broader trend.[CR-LF][CR-LF]Last week UHC announced the lab companies — AmeriPath/DermPath, a division of Quest Diagnostics; BioReference and its GeneDx business; Invitae; Laboratory Corporation of America; Mayo Clinical Laboratories; and Quest — it had selected as participants in its PLN program, which will go into effect on July 1, 2019.
Healthcare Technology Analyst Gill holds a conference call with CEO Rusckowski on May 2 at 1 pm hosted by JPMorgan.
Quest Diagnostics Incorporated executed a shelf takedown of $500 million aggregate principal amount of its 4.200% senior notes due 2029. Goldman Sachs, Mizuho Securities, Morgan Stanley, J.P. Morgan Securities and Wells Fargo Securities acted as joint book-running managers for the offering.[CR-LF][CR-LF]Quest Diagnostics Incorporated is the world’s leading provider of diagnostic information services.
The most recent version of an annual report issued by Quest Diagnostics indicates that 4.4 percent of workplace drug tests in 2018 were positive for illicit drugs, an increase over the 4.2 percent positivity rate in 2017 and the highest rate since 2004. According to Quest, the increase was largely fueled by marijuana use. Across the U.S. work force, the percentage of drug tests that were positive for marijuana rose from 2.6 percent in 2017 to 2.8 percent in 2018.
Genomic Vision (Paris:GV) (FR0011799907 - GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced its revenue and cash position1 at March 31, 2019. First quarter 2019 revenue In € thousands Q1 2019 Q1 2018 Revenue from R&D collaboration with Quest Diagnostics 75 75 Sales of products and
With the recent formation of the Get the Medications Right (GTMRx) Institute, Quest Diagnostics and the other institute co-founders aim to drive the use of advanced diagnostics for guiding patient treatment.[CR-LF][CR-LF]Launched this month by organizations including J&J, Medecision, and the American College of Clinical Pharmacy, the institute will function "as an advocacy entity" for companion diagnostics and pharmacogenomic testing, said Steve Goldberg, vice president, medical affairs, population health and chief health officer, health and wellness at Quest, and a member of the GTMRx board.